Sandoz Healthcare Access Challenge #SandozHACk returns, seeking digital solutions to local healthcare access challenges

NovartisSandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global competition that invites entrepreneurs and innovators in the field of digital technology to submit inspirational ideas with the potential to complement - or even positively disrupt - established approaches to driving access to healthcare.

#SandozHACk opens for entries, closing on November 30, 2018.

Universal access to healthcare is still arguably the largest unmet medical need and, while great strides continue to be made globally, access challenges vary hugely across geographies and communities. Therefore, a major step towards improving healthcare access globally is to identify and understand the specific needs of local communities.

"There are still two billion people in this world not getting the medicines they need. This is why we are launching Sandoz HACk as we aim to inspire and embrace the brave and innovative thinking of entrepreneurs and visionaries to improve access to healthcare around the world", said Richard Francis, Division Head and CEO of Sandoz.

Francis added: "Building on the inaugural Sandoz HACk, this year we are broadening the competition to anyone, anywhere, with an idea that uses digital technology to help address a local healthcare access challenge. By collaborating, we hope to create ambitious-yet-practical digital solutions that, with scale, could have a significant impact on people's lives."

Digital innovation promises cost-effective and practical solutions with the power to transform access. Last year, Sandoz HACk focused on m-health (mobile health). This year's theme is 'Leveraging Digital Technologies to Solve Healthcare Access Challenges': encouraging ideas that can drive patient access or help healthcare providers to reach more people.

Three shortlisted entrants, to be announced in January 2019, will receive support from Sandoz experts to develop their ideas and transform potential into real impact. Our three finalists will travel to the world's leading forward-focused gathering of creative minds, South by Southwest (SXSW; Austin, Texas) in March 2019, to explore, network and discover the latest innovative trends. Following in-person selection, one winner will be chosen and awarded seed funding and support from Sandoz, to help bring their idea to life.

For more details on how to enter the competition and terms and conditions, please visit: https://www.sandoz.com/making-access-happen/sandoz-hack

About Sandoz HACk

As the global leader in biosimilars, generic antibiotics and generic oncology medicines, Sandoz aims to play a leading role in making access happen for people around the world. Through Sandoz HACk we will use our expertise to bring access ideas in these areas, and beyond, to life. We believe that small ideas can spark big change and that, together, we can co-create ambitious-yet-practical solutions that break down access barriers around the world.

About Sandoz

Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2017 sales of USD 10.1 billion. In 2017, our products reached well over 500 million patients. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125,000 people of more than 140 nationalities work at Novartis around the world.

Most Popular Now

AstraZeneca COVID-19 vaccine Vaxzevria authorised …

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisat...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companie...

Takeda announces approval of Moderna's COVID-19 va…

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under...

Sanofi and GSK initiate global Phase 3 clinical ef…

Today, Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recomb...

Sanofi and GSK COVID-19 vaccine candidate demonstr…

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who h...

European Commission approves Venclyxto-based combi…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidi...

Novartis reaches milestone delivery of 1 billion c…

Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was s...

COVID-19 mRNA vaccines are immunogenic in pregnant…

Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age ...

Why are some COVID-19 vaccines working better for …

MSU researcher is studying, raising awareness about the role of sex in the efficacy of vaccines that make use of nanomedicine. If there's one take-home message for the...

Rogue antibodies wreak havoc in severe COVID-19 ca…

The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in ...

New vaccine platform: 'Two-one replicon-and-VLP-mi…

To stop the current SARS-CoV-2 pandemic, vaccines of high quality, safety, and efficacy are required. Scientists of the Paul-Ehrlich-Institut and the Ludwig Maximilian Un...

COVID-19 monoclonal antibodies reduce risk of hosp…

Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer compl...